Bedrolina

Bedrolina is a **standardized botanical cannabis product** developed by Bedrocan and presented by Bedrocan Canada as a high-CBD medicinal cannabis chemovar derived from *Cannabis sativa* L. cultivar Janna. It is characterized by an approximately **14% cannabidiol content and less than 1% tetrahydrocannabinol**, and is manufactured as a pharmaceutical-grade active pharmaceutical ingredient under standardized cultivation and production systems. Rather than being a single-molecule targeted therapy, Bedrolina is a whole-plant cannabis drug substance intended for medical use and for downstream manufacture of CBD-rich extracts, oils, ointments, and related cannabis-based pharmaceutical preparations. Publicly available information does not identify a single disease-specific internal clinical development program for Bedrolina, but positions it as a standardized medicinal cannabis product for the medical market and for use by drug developers.

Brand names

Bedrolina

Other names

Bedrolina-Bedrocan Canada-standardized cannabis chemovar-botanical cannabis productCannabis sativa L. JannaJanna